论文部分内容阅读
目的:研究晚期大肠癌使用FOLFOX或FOLFIRI方案全身化疗的疗效及安全性。方法:以“肠癌、化疗”为关键字,“奥沙利铂、伊利替康”或“FOLFOX、FOLFIRI”为二次检索关键字,搜索维普中文科技期刊数据库2000—2008年国内有关晚期大肠癌全身化疗的文献,并搜集所有文献信息,进行描述性分析。结果:共搜寻得到晚期大肠癌全身化疗有关FOLFOX、FOLFIRI方案文献283篇。最终有FOLFOX方案96篇、FOLFIRI方案16篇纳入分析。33篇提及中位生存期,30篇提及疾病进展时间。FOLFOX4方案有效率在26.1%~57.14%,FOLFOX6方案有效率在33.3%~48.6%,其他L-OHP+CF/5-FU方案有效率在26.5%~60%。FOLFIRI方案有效率在12.5%~48.2%。结论:国内晚期大肠癌全身化疗FOLFOX、FOLFIRI方案疗效与国际相仿,然方案具体运用尚不规范,临床试验纳入样本量相对较少,缺乏大样本多中心的临床随机对照试验,影响结果。
Objective: To study the efficacy and safety of systemic chemotherapy with FOLFOX or FOLFIRI in advanced colorectal cancer. METHODS: The key words of “bowel cancer and chemotherapy”, “oxaliplatin, irinotecan” or “FOLFOX, FOLFIRI” 2008 domestic literature about systemic chemotherapy of advanced colorectal cancer, and collect all the literature information, descriptive analysis. RESULTS: A total of 283 articles on FOLFOX and FOLFIRI regimens were obtained from a total of 50 patients with advanced colorectal cancer. Finally, 96 FOLFOX programs and 16 FOLFIRI programs were included in the analysis. 33 mentioned the median survival time, 30 mentioned the progress of the disease. The effective rate of FOLFOX4 regimen was 26.1% -57.14%, that of FOLFOX6 regimen was 33.3% -48.6%, and that of other L-OHP + CF / 5-FU regimen was 26.5% -60%. FOLFIRI program is effective at 12.5% ~ 48.2%. CONCLUSIONS: The efficacy of FOLFOX and FOLFIRI in patients with advanced colorectal cancer in China is similar to that in the international community. However, the specific application of the protocol is not standardized, and the clinical trials are relatively small in sample size.